Neurol 0,25

Quick links

Choose a section

Quick links to important sections

Advertisements

Neurol 0,25

Selected form

Advertisements
Advertisements

Overview of Neurol 0,25

Quick Facts

Property Description
Active ingredient Alprazolam
Form Tablet (Oral formulation)
Pharmacological class Benzodiazepine / Anxiolytic
General purpose Mitigation of acute tension and agitation
Origin Synthetic

Neurol 0,25: Identity and Classification

Neurol 0,25 is a prescription-only psychotropic agent classified within the Benzodiazepine pharmacological class, featuring Alprazolam as its active ingredient. This compound belongs specifically to the triazolo-benzodiazepine subclass. The medicine is a wholly synthetic entity that functions primarily as an anxiolytic, a designation for its efficacy in managing states of acute, overwhelming distress. Its identity as a Central Nervous System (CNS) depressant is consistent with its intended effect of modulating neuronal activity to stabilize heightened emotional states. Alprazolam is a standard agent used to manage anxiety and panic states.

Composition and Therapeutic Form

The medicine is supplied as an oral formulation in the form of tablets, with Alprazolam being the sole active ingredient. This is a single component product, meaning its clinical effects are derived entirely from the pharmacological action of the Alprazolam substance. The specific oral formulation as a tablet ensures a consistent route of administration, which is a requirement for controlled substances. Alprazolam is noted for its relatively fast-acting profile compared to some other Benzodiazepines, which positions it for use in situations demanding rapid relief of severe tension.

General Purpose of the Anxiolytic Action

The general purpose of the medication is to reduce excessive tension and overstimulation within the nervous system, thereby supporting emotional equilibrium. The anxiolytic action functions by enhancing natural calmness through the brain’s inhibitory pathways, as the substance interacts with GABA receptors. This activity is designed to mitigate the mental and physical manifestations of intense internal distress, including pervasive worry, agitation, and accompanying physical symptoms such as muscle tension. This mechanism allows for the quick stabilization of acute, overwhelming emotional and physical responses, providing immediate relief from debilitating emotional overload.

Regulatory References

  1. NIH StatPearls - Alprazolam
  2. MedlinePlus Drug Information - Alprazolam
Advertisements

What side effects are possible with Neurol 0,25?

Official Safety Profile and Adverse Reactions

The regulatory safety profile for Alprazolam (the active ingredient in Neurol 0,25) organizes potential side effects by frequency and the body system affected, based on clinical data and post-marketing experience. Adverse reactions are classified according to standardized frequency categories used in regulatory documents.

Frequency Classification Examples of Documented Effects (System-Organ Class)
Very Common (1/10) Sedation, Somnolence (Drowsiness)
Common (1/100 to < 1/10) Ataxia (impaired coordination), Memory impairment, Cognitive disorder, Fatigue, Irritability, Dry mouth, Constipation, Changes in appetite/weight
Uncommon (1/1,000 to < 1/100) Aggression, Hallucinations, Muscle weakness
Not Known (Cannot be estimated) Mania, Hypomania, Hepatitis, Angioedema

Serious adverse reactions are explicitly noted in regulatory labeling. These include the documented risks of physical and psychological dependence and potentially life-threatening withdrawal reactions upon cessation. Furthermore, use with other Central Nervous System (CNS) depressants, such as opioids, significantly increases the risk of severe respiratory depression and coma. Paradoxical reactions, involving heightened hostility or agitation, are also documented as potential side effects.

Safety notes tied to duration and population are defined in official documents. Effects like sedation are generally more likely at the start of treatment or following a dose increase. Conversely, the risks of dependence and severe withdrawal increase with longer treatment duration and higher exposure. Specific safety considerations exist for older adults due to increased sensitivity to CNS effects, which may increase the risk of falls and oversedation. The medicine is contraindicated in conditions such as known hypersensitivity to benzodiazepines, acute narrow-angle glaucoma, and severe hepatic (liver) impairment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Neurol 0,25 overdose describes a spectrum of Central Nervous System (CNS) depression. Manifestations typically include severe drowsiness, confusion, impaired coordination (ataxia), slurred speech, reduced reflexes, and potential progression to coma. The physiological systems primarily affected are the CNS and the respiratory system, as stated in prescribing information.

A severe or life-threatening outcome, specifically profound sedation, respiratory depression, coma, and death, is explicitly associated with the co-ingestion of Neurol 0,25 with other CNS depressants, such as alcohol or opioids. Regulatory documentation mandates that individuals must seek emergency medical care immediately if the affected person has trouble breathing, has collapsed, or cannot be awakened (unresponsive).

Official management procedures require general supportive measures, including the maintenance of an adequate airway and continuous monitoring of vital signs. The agent Flumazenil, a benzodiazepine receptor antagonist, may be useful as an adjunct in reversing the sedative effects, but official guidance warns it is not a substitute for proper management and notes a risk of seizure. Population-specific considerations include an increased risk of oversedation and prolonged drug elimination rates in elderly or debilitated patients and those with alcoholic liver disease. The official structure is a regulatory constraint, emphasizing that treatment is supportive and emergency action is necessary for life-threatening symptoms.

Advertisements

Therapeutic Uses of Neurol 0,25

Alleviating Symptoms of Pathological Anxiety Disorders

This medication is applied across domains where additional symptomatic support is needed, primarily to manage the therapeutic areas of Generalized Anxiety Disorder (GAD) and the short-term relief of anxiety symptoms. This is relevant in contexts marked by increased discomfort or tension when anxiety becomes pathological. It helps address symptom clusters that include pervasive worry, persistent agitation, and severe emotional restlessness that can interfere with daily functioning. The treatment may assist with managing these symptoms, contributing to improved day-to-day comfort during symptomatic periods.

Controlling Acute Panic Attacks and Intense Fear

The medication plays a role in managing symptoms of Panic Disorder, which is relevant in conditions characterized by periods of heightened symptoms. The medication is applied to address conditions such as Generalized Anxiety Disorder, Panic Disorder (with or without agoraphobia), and anxiety that may be associated with depressive symptoms. This is commonly used in situations involving symptoms related to heightened physiological activity, such as unexpected episodes of intense fear, palpitations, and trembling. It is applied when appropriate and supportive relief is needed to manage acute states. The medication may contribute to improved comfort during periods of heightened symptoms by addressing the symptoms that become temporarily overwhelming.

Relief of Somatic and Functional Distress

Neurol 0,25 is relevant for managing symptoms that interfere with daily functioning, including the pronounced physical manifestations of severe anxiety. It is used across domains involving certain distressing symptoms that create noticeable functional strain. This symptomatic assistance supports patients during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Acute Distress
Therapeutic Focus Easing the intensity and frequency of Panic Attacks.
Symptom Category Symptoms related to increased neurological or muscular activity (e.g., trembling, palpitations).
Clinical Context Applicable in clinical settings that involve acute or unstable symptom patterns.
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Neurol 0,25 — official regulatory information

Eligibility scope Status as per Regulatory Label
Populations for whom use is allowed Adults (18 years and older) who do not have documented contraindications.
Populations for whom use is not recommended Individuals under 18 years of age (safety and effectiveness not established); pregnant individuals; breastfeeding individuals.
Populations for whom use is contraindicated Patients with known hypersensitivity to alprazolam or other benzodiazepines; patients with Acute Narrow Angle Glaucoma; patients taking strong Cytochrome P450 3A (CYP3A) Inhibitors (e.g., ketoconazole, itraconazole).

Age-related eligibility rules: Use is not established in the pediatric population. Older adults require use with caution, and a lower initial dose is recommended due to potential increased sensitivity.

Condition-specific eligibility rules: Use is contraindicated in patients with certain conditions like Severe Hepatic Insufficiency in some regions. Caution is required in patients with renal or hepatic impairment (non-severe).

Pregnancy and lactation eligibility status: Use is not recommended during pregnancy due to the risk of Neonatal Sedation and Withdrawal Syndrome. Use is advised against during lactation due to potential risks to the infant.

Eligibility-related restrictions: The concomitant use of this medicine with opioids is a restricted condition and must be reserved only for patients when alternative treatments are inadequate, as per the FDA Boxed Warning. Caution is required in patients with a history of alcohol or drug dependence.


Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility based on patient demographics and pre-existing physiological conditions. The label establishes use primarily for the adult population, while clearly prohibiting populations with certain allergies or those taking specific metabolic pathway inhibitors. Eligibility is restricted and requires special caution in groups with organ impairment or advanced age.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Neurol 0,25 (alprazolam) is primarily metabolized by the Cytochrome P450 3A (CYP3A) enzyme system, which dictates most significant drug interactions. Official regulatory information highlights two main types of clinically relevant interactions: pharmacokinetic modulation and pharmacodynamic additive effects.


Pharmacokinetic Interactions (Level Changes)

  • CYP3A Inhibitors: Co-administration with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole) is contraindicated due to the substantial increase in alprazolam plasma concentrations. Other inhibitors (e.g., nefazodone, fluvoxamine) also require caution, as they increase the drug's exposure by reducing its metabolism.
  • CYP3A Inducers: Substances that induce CYP3A (e.g., carbamazepine) can decrease alprazolam plasma levels, which may reduce its expected effect.

Pharmacodynamic Interactions (Additive Effects)

  • Opioids and CNS Depressants: Concomitant use with opioids or other Central Nervous System (CNS) depressants (including alcohol, antipsychotics, and sedatives) carries a risk of additive effects, potentially leading to profound sedation and respiratory depression. Official labeling states that co-prescribing with opioids should be reserved for patients when no alternative options are adequate.

Other Documented Interactions

  • Digoxin: Alprazolam has been shown to increase digoxin concentrations, requiring close patient monitoring for signs of digoxin toxicity.
  • Smoking: Cigarette smoking may reduce alprazolam concentrations, influencing therapeutic response.
Advertisements

Mechanism of Action

Modulation of the GABA A Receptor System

Neurol 0,25 (Alprazolam) acts as a Positive Allosteric Modulator (PAM), targeting a specific site on the gamma-Aminobutyric acid type A receptor ( GABA A receptor). The GABA A receptor is the primary mediator of inhibition in the central nervous system (CNS). The drug enhances the effect of the endogenous neurotransmitter GABA, effectively boosting the brain's existing inhibitory signals.


Causal Cascade: From Ion Flow to Reduced Excitability

The molecular interaction initiates a sequential change in cellular activity: enhanced GABA action causes the receptor's chloride ion ( Cl^-) channel to open more frequently, allowing Cl^- ions to rush into the nerve cell. This influx causes the neuron to become hyperpolarized (more negatively charged), which reduces its responsiveness to excitatory input. This fundamental mechanism results in the physiological state of generalized neuronal inhibition across the CNS.


Systemic Enhancement of Inhibitory Pathways

The widespread inhibition of neuronal activity affects pathways within the limbic system, which governs arousal and emotional processing. By raising the overall inhibitory tone, the mechanism functionally limits high-frequency signaling in these circuits. This systemic enhancement of inhibition results in a physiological state characterized by reduced CNS excitability and modulation of skeletal muscle tone.

Advertisements

Dosage and Administration Information

How to Use Neurol 0,25: Official Administration Guidelines

Neurol 0,25, an immediate-release Alprazolam tablet, is used exclusively via the oral route of administration. Official usage protocols define precise initial dosing, frequency, and modification schedules that must be followed. The tablets may be taken without regard to food.


Standard Labeled Dosing Regimens

Dosing recommendations are typically divided and administered three times daily. The established starting doses and maximum limits differ based on the therapeutic context.

Indication Recommended Starting Dose (Oral) Maximum Recommended Daily Dose
Generalized Anxiety Disorder (GAD) 0.25 mg to 0.5 mg 4 mg
Panic Disorder 0.5 mg 10 mg (studied range)

Rules for Adjustment and Discontinuation

Usage involves a careful process of titration and cessation. Any adjustment to the dosage, whether increasing or decreasing, should occur gradually, typically at intervals of every three to four days. The objective is to establish the lowest possible effective dose.

For specific populations, lower starting doses are mandated. For older adults and debilitated patients, as well as those with severe hepatic impairment, the recommended starting oral dose is 0.25 mg, administered two or three times daily to minimize over-sedation.

Discontinuation is a managed process; the dosage must be reduced gradually, with a standard reduction rate of no more than 0.5 mg every three days. This gradual tapering is a mandatory component of the overall use protocol.

Advertisements

Recent Clinical Evidence

Neurol 0,25: Recent Clinical Evidence

Evidence for Use in Panic Disorder

Research for Alprazolam, the active ingredient in Neurol 0,25, was studied for its role in research exploring Panic Disorder, a condition characterized by episodic or acute changes involving sudden, intense fear. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) comparing the compound to a placebo and sometimes with active reference agents. These trials measured changes in the frequency of panic attacks and examined outcomes related to episodic or acute changes in symptoms. Studies monitored these responses over defined time intervals, typically lasting around 4 to 10 weeks.

Studies monitored patterns observed in the research where measurements indicated patterns related to change in the frequency of panic attacks compared to the measurements taken from the placebo groups. Research describes changes measured during the study period on global scores that assessed a patient’s overall condition, and studies also monitored rates of patient discontinuation. Systematic reviews of the data indicate that findings regarding the size of the observed pattern of change may vary between the publicly available literature and the data provided directly to health authorities.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Research examined settings with varying symptom burdens for Generalized Anxiety Disorder (GAD) and related short-term anxiety symptoms. Studies in this area mainly include short-term clinical trials which measured outcomes related to systemic or functional imbalance using standardized scales. These studies explored changes in the typical symptom patterns of GAD, focusing on measures of pervasive worry, general restlessness, and outcomes related to physical discomfort, such as muscle tension.

Unanswered Questions and Research Gaps

A key area of uncertainty is that the follow-up durations were limited, and therefore, research on long-term outcomes is not fully established. Additionally, comparative evidence is lacking in certain areas, such as detailed comparisons against newer first-line pharmacological treatments. The findings describe group patterns, not personal outcomes, and the research provides context but does not determine whether an individual will respond similarly to the patterns observed in the trials.

Key Studies & References

  1. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neurol 0,25 (FAQ)


Q: How quickly does the effect of Neurol 0,25 start to work?

According to the official product information, the active ingredient, Alprazolam, is absorbed quickly after taking the tablet. Peak concentrations in the blood are typically reached within one to two hours following oral administration.

Q: How long does the effect of one dose of Neurol 0,25 usually last?

Pharmacological studies indicate that the drug's mean elimination half-life in healthy adults is approximately 11.2 hours. This measurement helps determine how quickly the body removes the drug, though the actual duration of effect can vary between individuals.

Q: Is it true that Neurol 0,25 can be habit-forming if used for a long time?

Official warnings note that continued use of medicines in this class may lead to clinically significant physical dependence. The risk of dependence is documented to increase with both longer duration of treatment and a higher daily dosage.

Q: What happens if you stop taking Neurol 0,25 suddenly?

Regulatory documents warn that abruptly stopping the medicine or rapidly reducing the dosage after continued use can precipitate acute withdrawal reactions, which are documented to be potentially life-threatening. For this reason, official protocols require a gradual dosage reduction when stopping the medicine.

Q: What is the risk of developing dependence on Neurol 0,25?

Dependence is a documented risk associated with this class of medicine. Official prescribing information indicates that the risks of developing physical dependence and experiencing withdrawal symptoms increase with both a longer period of use and a higher daily dosage.

Q: Can a person develop withdrawal symptoms from Neurol 0,25 even with low doses?

The official guidance describes gradual dosage reduction as a mandatory requirement for discontinuation. The risk of withdrawal reactions is documented to occur whenever the dosage is reduced or the medicine is stopped.

Q: Is Neurol 0,25 known by any other brand names?

Yes, the active ingredient in this medicine is Alprazolam, which is the generic substance. This substance is also marketed under various brand names in different regions, including Xanax in the United States.

Q: What is the difference between Neurol 0,25 and other higher doses of the same drug?

Different tablet strengths, such as 0.25 mg, are manufactured to allow flexibility in treatment. This strength allows for titration, meaning the ability to start treatment at a low amount and adjust gradually toward the lowest possible effective dose.

Q: Can Neurol 0,25 cause memory problems?

Memory impairment is listed in the official safety profile as a documented common side effect reported in clinical trials. It is part of the central nervous system effects associated with this type of medicine.

Q: Is Neurol 0,25 the same as similar-sounding prescription drugs?

Neurol 0,25 contains Alprazolam, which is classified as a specific triazolo analog of the 1,4 benzodiazepine class of compounds. While it belongs to the wider benzodiazepine family, this specific classification distinguishes it from other similar medicines in that class.

Q: Do you feel 'high' or sleepy when taking Neurol 0,25?

Sedation and drowsiness (somnolence) are documented as very common side effects. Regulatory notes also indicate that some changes in thinking or behavior that have occurred in people taking the medicine are described as being like those seen in people who drink alcohol.

Q: Are there any foods or drinks to avoid when using Neurol 0,25?

Official drug labeling explicitly advises against consuming alcohol due to the risk of additive central nervous system effects. Additionally, grapefruit and grapefruit juice are noted to potentially interact with the medicine, which could lead to increased effects.

Q: Can Neurol 0,25 affect your ability to drive or operate machinery?

Official warnings document that due to the risk of central nervous system (CNS) depression and impaired performance, patients using this medicine should be cautioned against operating machinery or driving a motor vehicle.

Q: Is it normal to feel a bit restless after taking Neurol 0,25?

While the medicine's main effect is to increase calming signals in the brain, documented adverse effects known as paradoxical reactions can occur. These reactions can involve heightened emotional states, including symptoms such as agitation or hostility.

Q: Why is the 0,25 mg dose specifically available?

The 0.25 mg strength is the recommended starting oral dose for the acute treatment of Generalized Anxiety Disorder in certain patients. Furthermore, it is the specified initial dose recommended for older adults and debilitated patients due to their increased sensitivity.

Q: Are there any long-term health concerns associated with using Neurol 0,25?

The systematic clinical studies used to demonstrate the medicine's effectiveness were officially limited to short-term durations (up to 4 months for GAD). For use beyond these periods, the documented risks of dependence and withdrawal are noted to increase with longer treatment duration.

Q: Does Neurol 0,25 interact with commonly used over-the-counter pain relievers?

Official prescribing information warns that concomitant use with other Central Nervous System (CNS) depressants carries a risk of additive effects, such as profound sedation and respiratory depression. Some over-the-counter products, if they contain sedating ingredients, would fall into this caution category.

Q: Do people typically need to use Neurol 0,25 only as needed, or every day?

The recommended starting oral dosage for both approved indications is typically administered in divided doses, three times per day. The specific pattern of use is established by the treating healthcare professional.

Q: Does Neurol 0,25 affect appetite or cause weight changes?

Yes, changes in appetite and weight are reported as common side effects in clinical trial data. This includes both increased appetite leading to weight gain and decreased appetite potentially leading to weight loss.

Q: Are there specific times of day that are best for taking Neurol 0,25?

The immediate-release tablets are generally administered in divided doses three times per day. Official guidelines state the tablets may be taken without regard to food, allowing flexibility for the patient's schedule.

Q: Can someone become tolerant to the effects of Neurol 0,25 over time?

Official guidance requires doctors to periodically reassess the usefulness of the drug for the individual patient. This is due to the short-term duration of the clinical trials and the need to ensure the lowest effective dose is maintained over time.

Q: Is there a maximum duration of time that Neurol 0,25 is studied for use?

The demonstrations of the medicine's effectiveness by systematic clinical study are officially limited to short-term periods: 4 months in duration for Generalized Anxiety Disorder and 4 to 10 weeks for Panic Disorder.

Q: How do doctors monitor the effectiveness of Neurol 0,25?

The official prescribing information advises doctors to use the lowest possible effective dose. It also mandates that the healthcare provider frequently assess the patient's need for continued treatment over time.

Q: Can Neurol 0,25 affect blood pressure?

Hypotension, which is low blood pressure, is documented as a possible cardiovascular adverse effect reported in clinical trials involving this medicine.

Q: Is it possible for Neurol 0,25 to make existing symptoms feel worse?

Official safety notes document that paradoxical reactions, involving symptoms like agitation or hostility, can occur. Additionally, the medicine can cause or worsen existing symptoms of mental depression.

Q: What is the risk of overdose with Neurol 0,25?

Overdose is a documented risk, with symptoms potentially ranging from drowsiness (somnolence) to coma. The risk of life-threatening outcomes, including respiratory depression and death, is substantially increased when the drug is taken with other central nervous system depressants, such as alcohol or opioids.

Q: What should be done if a dose of Neurol 0,25 is forgotten?

Patient information leaflets describe taking the dose as soon as it is remembered, unless it is close to the time for the next scheduled dose. Patients are advised against taking a double dose.

Advertisements

How should Neurol 0,25 be stored and disposed of?

How to Store and Dispose of Neurol 0,25?

Alprazolam tablets (Neurol 0,25 mg) must be handled and stored according to specific regulatory requirements to ensure potency, stability, and security.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed, and protect from moisture and high humidity.
Security The medicine must be stored out of the sight and reach of children due to its controlled substance classification.

Disposal Instructions

As a controlled substance, disposal must follow official guidelines. The preferred method is to use established drug take-back programs or DEA-authorized collection sites for unused or expired tablets. The product is not on the flush list, meaning it should not be flushed down a toilet or sink. If a take-back program is unavailable, disposal in household trash requires mixing the tablets with an undesirable material, such as dirt or used coffee grounds, and sealing the mixture before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neurol 0,25 found in:

A-Z Index: